Lonza Group AG stock (CH0013841017): Swiss CDMO share in focus after latest quarterly update and analyst estimates
08.06.2026 - 09:56:22 | ad-hoc-news.de
Lonza Group AG shares on the SIX Swiss Exchange remain on the radar of Swiss and international investors after the Basel-based contract manufacturer reported its latest quarterly results in April 2026 and provided an update on its medium-term strategy for its biologics and small-molecule businesses, prompting analysts to revisit their earnings models and valuation assumptions for the stock.
As a key component of the Swiss equity market, Lonza Group is traded on SIX Swiss Exchange under the ticker LONN and is widely followed as one of the larger names in the Swiss Performance Index, giving the stock a prominent role for both domestic and international investors seeking exposure to Switzerland’s life-sciences sector.
According to SIX Swiss Exchange data as of 04/24/2026, the stock traded around CHF 490.00 shortly after the company released its first-quarter 2026 trading update, which outlined the latest development in its biologics manufacturing and small-molecule services businesses and offered investors more detail on the demand environment from pharmaceutical and biotechnology clients.
In Germany, Lonza Group is also available for trading via platforms such as Tradegate under the same ISIN CH0013841017, where the stock typically trades in euro and provides an additional access point for investors who prefer to transact on German venues while still tracking the primary Swiss listing.
From the perspective of the issuer’s home country, Switzerland, the company’s latest quarterly communication and the continued visibility of the share on SIX Swiss Exchange ensure that Lonza Group remains integrated into the broader Swiss equity narrative, alongside other life-sciences names listed in Zurich.
As of: 08.06.2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: Lonza Group
- Sector/industry: Contract development and manufacturing / life sciences
- Headquarters/country: Basel, Switzerland
- Core markets: Europe, North America, Asia-Pacific
- Key revenue drivers: Biologics manufacturing, small-molecule services, cell and gene technologies, capsules and specialty ingredients
- Home exchange/listing venue: SIX Swiss Exchange (LONN)
- Trading currency: CHF
Lonza Group AG: core business model
Lonza Group AG operates as a contract development and manufacturing partner to pharmaceutical and biotechnology companies, providing outsourced services across biologics, small molecules and advanced therapies while generating most of its revenue from multi-year manufacturing contracts and long-term service agreements in its core biologics and small-molecule divisions.
What banks and research houses say about Lonza Group AG
Lonza Group AG’s position as a major contract manufacturer in the global life-sciences supply chain means the stock is closely followed by Swiss and international banks that regularly update their views following company disclosures and sector developments. These analyst assessments provide a snapshot of how professional investors interpret Lonza’s earnings power, capital expenditure plans and exposure to broader themes such as biologics outsourcing and cell and gene therapies.
According to MarketScreener consensus data as of 05/02/2026, a group of more than 15 analysts covering Lonza Group AG has an average recommendation in the neutral to positive range, with an aggregate 12-month price objective around CHF 520.00 per share, reflecting expectations for mid-single-digit to low double-digit percentage upside versus recent trading levels and incorporating assumptions about the pace of ramp-up at key biologics sites, utilization rates and capital intensity across the network.
The consensus figures published by MarketScreener indicate that analysts expect Lonza Group AG to continue to grow revenue and earnings over the next few years, albeit with an emphasis on disciplined capital allocation and a focus on higher-margin projects, as the company seeks to optimize its mix of contracts and manage the transition from large COVID-related manufacturing volumes to a more diversified portfolio of biologics and advanced therapies projects.
In addition to the MarketScreener compilation, individual banks such as UBS, Credit Suisse’s successor entities and other European research houses regularly issue standalone reports on Lonza Group AG, which typically include detailed segment-level forecasts for biologics, small molecules and cell and gene technologies, and commentary on how changes in client pipelines, regulatory developments and capacity expansions might affect utilization and profitability over the medium term.
When banks update their target prices and ratings, they often do so in response to new information from Lonza Group AG’s quarterly updates, capital markets presentations or strategic announcements, such as the company’s decisions on major investment projects, site expansions, potential partnerships, or any divestitures and portfolio optimizations that may be flagged to the market from time to time.
Because Lonza Group AG operates a globally diversified manufacturing network, the research community also tracks macroeconomic indicators, the funding environment for biotechnology companies and drug development pipelines when assessing the company’s earnings trajectory, all of which are incorporated into the model-based price targets that feed into the consensus compiled by aggregators such as MarketScreener.
For retail investors, the existence of a broad analyst coverage base for Lonza Group AG means that the stock is rarely without updated estimates and commentary, and that new information from the company tends to be reflected in consensus estimates and valuation metrics with relatively short time lags compared with less-followed issuers.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Lonza Group AG
Investors and commentators frequently discuss Lonza Group AG’s quarterly updates, capacity expansion plans and analyst estimate changes on social media and video platforms, offering an additional, more informal perspective on the Swiss contract manufacturer’s share price performance and strategic direction.
Conclusion
Lonza Group AG’s recent quarterly communication from Switzerland and the associated trading activity on SIX Swiss Exchange keep the stock in focus for investors looking at the country’s life-sciences sector. The company’s role as a large contract development and manufacturing partner for pharmaceuticals and biotechnology clients means analyst coverage and consensus estimates, such as those compiled by MarketScreener, remain an important reference point for market participants assessing its medium-term prospects.
While the share price will continue to respond to new information on capacity utilization, project wins, capital expenditure and broader sector dynamics, Lonza Group AG’s established position in biologics and related services ensures that its stock is likely to remain a key name in discussions around Swiss healthcare and life-sciences equities.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
